Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.

Abstract

The efficacy and safety of the 6-dose regimen of artemether-lumefantrine were assessed in an open randomized trial in children and adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand between November 1997 and March 1998. 200 patients were enrolled in 2 centres: 150 received artemether-lumefantrine (i.e., a median total dose of 9·6 mg/kg [interquartile range 8·7–10·7] and 57·9 mg/kg of lumefantrine [52·4–64·0]) and 50 the standard combination of artesunate (12 mg/kg over 3 d) and mefloquine (25 mg/kg). All patients had rapid initial clinical and parasitological responses. The 28 d cure rates were high: 97·7% (95% confidence interval [95% CI] 93·5–99·5%) for artemetherlumefantrine and 100% (95% CI 92·5–100%) for artesunate-mefloquine. The 6-dose regimen of artemether-lumefantrine was better tolerated than, and as effective as, artesunate-mefloquine, the current standard treatment in this area of multidrug-resistant P. falciparum malaria.